Relmada Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Mar 19, 2024 and accepted by EDGAR at Mar 19, 2024, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2023-01-01 to 2023-12-31 | $54.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −$103.7m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$98.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$3.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$3.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 30,099,203 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$51.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-12-31 | $4.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $97.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $97.6m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $12.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $12.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | $85.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-24-024013. Last ingested by Listed: Oct 24, 2026, 15:13 ET. Listed shows no prices and gives no investment advice.